Skip to main content

APOLIPOPROTEINS

Objective



Cardiovascular diseases still represent the major cause of death and invalidity in our Western society. Clinical and epidemiological studies have established that the prevalence and incidence of these diseases are associated with serum lipoprotein concentrations. In the last years there has been a growing interest for the protein moiety of the lipoproteins called the "apolipoproteins", the determination of which offers a more discriminative diagnosis for coronary heart disease.

The aim of the project is to assist in the standardization of apolipoprotein (Apo) assays. The project includes the preparation of purified Apo AI, Apo AII and possibly Apo B to be used as calibrators for the determination of these Apo's in serum. The next step will concern methodological development and might result in the certification of serum reference materials.

RESULTS

The purification of Apo AI and Apo AII is completed. The stability of the lyophilized preparations appears to be satisfactory. The certification analysis is performed by aminoacid analysis to assign a mass concentration to each of the purified Apo's. The Apo materials have been certified with the following mass concentrations :

for Apo AI, CRM 393 (1.06 +/- 0.05) g/l
for Apo AII, CRM 394 (0.321 +/- 0.019) g/l.

The results are presented in EUR report 13393 (1991).

Coordinator

UNIVERSITY OF GLASGOW
Address
University Avenue
Glasgow
United Kingdom

Participants (7)

Algemeen Ziekenhuis Sint Jan
Belgium
Address

Brugge
Behringwerke AG
Germany
Address

35001 Marburg
Boehringer Mannheim GmbH
Germany
Address

Penzberg
Diagnostics Pasteur-Kallestad
France
Address

Steenvoorde
INSTITUT PASTEUR DE LILLE
France
Address
Rue Du Professeur Calmette 1
59019 Lille
UNIVERSITÀ DEGLI STUDI DI MILANO
Italy
Address

Milano
University of Lund
Sweden